This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
This page refreshes automatically every 30 mins. Press F5 to update manually
For a more detailed explanation of Upgrades/Downgrades see Link
Key: (?) = Upgraded, (?) = Downgraded, (-) = Maintained
| Stock | Broker Update |
| 4imprint Group | Finncap initiates with Buy; TP 752p |
| A.P.R. Energy | UBS ups to neutral from sell; ups TP to 900p from 800p |
| AstraZeneca | UBS initiates with Buy; TP 4000p |
| Cable & Wireless Communications | UBS downgrades to neutral from Buy; ups TP to 55p from 50p |
| Capita | UBS ups to Buy from neutral; ups TP to 1200p from 1000p |
| Capital & Counties Properties | Morgan Stanley ups TP to 390p from 370p, overweight |
| Earthport | Panmure ups TP to 52p from 34p, Buy |
| Easyjet | Liberum downgrades to Hold from Buy |
| Flybe | Liberum ups TP to 130p from 90p, Buy |
| Glaxosmithkline | UBS initiates with neutral; TP 1650p |
| Greggs | Citigroup ups TP to 510p from 430p, neutral |
| HomeServe | UBS ups to Buy from neutral; ups TP to 320p from 270p |
| International Consolidated Airlines | HSBC downgrades to neutral from overweight; ups TP to 450p from 430p |
| Ithaca Energy | Liberum cuts TP to 196p from 210p, Buy |
| Morgan | Berenberg initiates with Buy; TP 370p |
| Persimmon | HSBC ups TP to 1500p from 1395p, overweight |
| Rentokil | Panmure downgrades to sell |
| Rockhopper Exploration | SocGen ups TP to 162p from 135p, Hold |
| Ryanair | Liberum downgrades to Hold from Buy |
| Serco | UBS downgrades to neutral from Buy |
| Sinclair IS Pharma | Finncap ups TP to 48p, Buy |
| Spirent | UBS cuts TP to 90p from 130p, neutral |
| Tesco | HSBC cuts TP to 300p from 340p, underweight |
| WM Morrison | HSBC cuts TP to 200p from 260p, underweight |
| WM Morrison | Citigroup cuts TP to 250p from 280p, neutral |
| Source: Reuters News, AlphaTerminal, Dow Jones Newswires | |
Source: Bloomberg, Reuters News, AlphaTerminal, Dow Jones Newswires
T111his research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research